C
Corium International
Engages in the development of advanced transdermal drug delivery technologies and products
About Corium International
Corium Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative healthcare therapies for the central nervous system (CNS). The company focuses on providing clinicians with advanced treatment options that benefit patients, their families, and caregivers. Corium's lead investigational product, Corplex Donepezil, is a transdermal formulation of donepezil, commonly prescribed for Alzheimer's disease, designed to deliver sustained and controlled doses over a week. Additionally, Corium is set to lead the commercialization of KP415, an investigational product for Attention Deficit Hyperactivity Disorder (ADHD) developed by KemPharm, Inc. This product aims to offer a new treatment option for ADHD patients, pending regulatory approval. Corium operates in the biopharmaceutical market, targeting healthcare providers and patients in need of CNS therapies. The company's business model revolves around developing proprietary transdermal technologies and partnering with other pharmaceutical firms to commercialize their products. Revenue is generated through product sales, licensing agreements, and milestone payments from partnerships. Keywords: transdermal solutions, CNS therapies, Alzheimer's treatment, ADHD medication, biopharmaceutical, commercialization, donepezil, KP415, healthcare innovation, patient care.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1995
- Headquarters
- Menlo Park, United States
- Listing
- IPO 2014
- Employees
- 269
- Open positions
- None listed
- Dealroom signal
- 27.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Dermatology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Corium International.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Oct 2022 | $100M | $400M | Webster Equity Partners | ↗ |
| DEBTDebt | Sep 2021 | $235M | — | Hercules Capital | ↗ |
Growth signals
Latest recorded traffic for Corium International is 1.9K monthly website visits, up 163.9% over the last three months. Corium International's team declined 17.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
Essex Woodlands Health Ventures- ACAphelion Capital
- QPQuantum Technology Partners
Hercules Capital
Webster Equity Partners
Other known investors1 additional known investor
Gurnet Point Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Corium International on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Corium International’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.